Withdrawn
NA
INTERVENTIONAL
NCT01026363
hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The human immune system produces a protein called hCAP18 (also known as LL-37 or cathelicidin). This protein is believed to help the body to fight infections. Studies suggest that vitamin D may important in the production of hCAP18. This study is designed to test the ability of two different forms of vitamin D to affect levels of hCAP18. Vitamin D and hCAP18 levels will be measured during an initial visit. Individuals who are vitamin D deficient will be randomly assigned to receive one of two forms of vitamin D for two weeks. After this, follow-up levels will be measured.
Interventions
Name:
Ergocalciferol
Type:
DRUG
Description:
Ergocalciferol 50,000 IU capsule, one dose every other day x 5 doses
Name:
Calcitriol
Type:
DRUG
Description:
0.25 mcg tablet once daily for 14 days
Primary Outcomes
Measure:
hCAP18 levels
TimeFrame:
2 weeks
Description:
Trial Information
NCT ID
NCT01026363
Status
Withdrawn
Study Type
INTERVENTIONAL
Phases
NA
Sponsor
Massachusetts General Hospital
Last Updated
December 15, 2025